Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jayesh Desai

Showing results (71-80 of 179) with videos related to

Pageof 18
Sort By:
Cancer Medicine|May 23, 2022
Mesenchymal chondrosarcoma: An Australian multi-centre cohort studyMadeleine C Strach, Peter S Grimison, Angela Hong, et al.
Targeted Oncology|May 27, 2014
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancerFiona Day, Andrea Muranyi, Shalini Singh, et al.
The Oncologist|December 25, 2024
A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profilingSubotheni Thavaneswaran, Hao-Wen Sim, John Grady, et al.
Cell Reports. Medicine|October 18, 2023
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumorsSophia Frentzas, Hui K Gan, Rasha Cosman, et al.
Clinical Colorectal Cancer|April 18, 2015
Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved SurvivalNatalie Turner, Ben Tran, Phillip V Tran, et al.
Internal Medicine Journal|March 20, 2019
Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in AustraliaRachel Delahunty, Margaret Lee, Hui-Li Wong, et al.
British Journal of Cancer|February 16, 2023
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumoursJayesh Desai, Peter Fong, Victor Moreno, et al.
Annals of Internal Medicine|November 8, 2006
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumorsJayesh Desai, Leila Yassa, Ellen Marqusee, et al.
Internal Medicine Journal|November 2, 2016
Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancerCaitlin Murphy, Natalie Turner, Hui-Li Wong, et al.
Oncoimmunology|September 14, 2016
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancerRosemary Millen, Jordane Malaterre, Ryan S Cross, et al.
Pageof 18

Showing results (71-80 of 179) with videos related to

Sort By:
Pageof 18
Cancer Medicine|May 23, 2022
Mesenchymal chondrosarcoma: An Australian multi-centre cohort studyMadeleine C Strach, Peter S Grimison, Angela Hong, et al.
Targeted Oncology|May 27, 2014
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancerFiona Day, Andrea Muranyi, Shalini Singh, et al.
The Oncologist|December 25, 2024
A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profilingSubotheni Thavaneswaran, Hao-Wen Sim, John Grady, et al.
Cell Reports. Medicine|October 18, 2023
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumorsSophia Frentzas, Hui K Gan, Rasha Cosman, et al.
Clinical Colorectal Cancer|April 18, 2015
Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved SurvivalNatalie Turner, Ben Tran, Phillip V Tran, et al.
Internal Medicine Journal|March 20, 2019
Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in AustraliaRachel Delahunty, Margaret Lee, Hui-Li Wong, et al.
British Journal of Cancer|February 16, 2023
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumoursJayesh Desai, Peter Fong, Victor Moreno, et al.
Annals of Internal Medicine|November 8, 2006
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumorsJayesh Desai, Leila Yassa, Ellen Marqusee, et al.
Internal Medicine Journal|November 2, 2016
Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancerCaitlin Murphy, Natalie Turner, Hui-Li Wong, et al.
Oncoimmunology|September 14, 2016
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancerRosemary Millen, Jordane Malaterre, Ryan S Cross, et al.
Pageof 18